Aurora Cannabis Launches First Domestically Grown Medical Cannabis Brand in Germany Under New Cultivation License

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) has launched IndiMed, its first German-cultivated medical cannabis brand, manufactured at their EU-GMP facility in Leuna, Germany. This development follows Germany's recent cannabis decriminalization and positions Aurora as one of only three licensed cultivators in the country.

The initial product release is Island Sweet Skunk, a dried flower sativa variant containing 20% THC and <1% CBD, scheduled for availability on January 27. The product is cultivated under GACP and EU-GMP guidelines, featuring hand-harvested flowers that undergo controlled drying and laboratory testing for purity and potency.

As the world's largest medical cannabis company in legal markets, Aurora's expansion in Germany demonstrates its commitment to serving the country's growing patient base with locally produced, high-quality medical cannabis products.

Positive

• One of only three licensed cultivators in Germany
• Launch of first domestically produced medical cannabis product in Germany
• EU-GMP certified manufacturing facility in Leuna operational

Negative

• None.

NASDAQ | TSX: ACB

Investment in the region continues with the launch of IndiMed, the company's first locally grown brand in Germany

EDMONTON, AB, Jan. 23, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces today the launch of the company's first German-cultivated medical cannabis product, under the brand IndiMed. Manufactured at Aurora's leading EU-GMP facility in Leuna, Germany, the new brand offers a supply of high-quality, locally grown and sold, medical cannabis for the country's expanding patient base.

"Aurora is proud to deliver to the rapidly growing German market our first domestically produced medical cannabis product – a significant step forward since Germany's move to decriminalize cannabis earlier this year," says Michael Simon, President, Aurora Europe (Interim). "As one of three facilities licensed to cultivate in Germany, we are uniquely positioned to offer domestic product from our EU-GMP facility in Leuna, Germany, which operates within Aurora's global manufacturing network. It is through our expertise in cultivation and deep commitment to science and innovation that we introduce IndiMed to the German patients."

The premium product launching from the IndiMed brand is Island Sweet Skunk, dried flower, sativa, 20% THC, <1 % CBD. Product is expected to be available on January 27. IndiMed is cultivated under GACP and EU-GMP guidelines to ensure pharmaceutical-grade quality. The flowers are harvested by hand, dried under controlled conditions, and tested in the state-of-the-art laboratory for purity and active ingredient content.

Aurora leads the global medical cannabis industry with unmatched expertise, driving innovation and progress. Its steadfast commitment to growth in the dynamic German market cements its position as the industry's unrivaled leader.

Aurora's expertise in navigating complex European regulatory frameworks and manufacturing high-quality medical cannabis positions the company as the preferred leader to drive progress in the German market with confidence. By continually setting new global benchmarks, Aurora reinforces its status as the world's largest medical cannabis company operating in nationally legal markets.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at   www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".                             

Forward Looking Information   

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of the Company's first German-cultivated medical cannabis product under the brand IndiMed, the timing for availability of that product in the German market, the Company's market leadership and status as the world's largest medical cannabis company operating in nationally legal markets, and the Company's ability to drive progress in the German market.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-launches-first-domestically-grown-medical-cannabis-brand-in-germany-under-new-cultivation-license-302357848.html

SOURCE Aurora Cannabis Inc.

FAQ

When will Aurora Cannabis (ACB) launch IndiMed in Germany?

Aurora Cannabis will launch IndiMed, its first German-cultivated medical cannabis product, on January 27, 2025.

What is the THC content of Aurora's new IndiMed Island Sweet Skunk product?

The IndiMed Island Sweet Skunk product contains 20% THC and less than 1% CBD.

How many companies are licensed to cultivate cannabis in Germany alongside Aurora (ACB)?

Aurora is one of only three facilities licensed to cultivate cannabis in Germany.

What quality standards does Aurora's IndiMed follow in Germany?

IndiMed is cultivated under GACP and EU-GMP guidelines to ensure pharmaceutical-grade quality, with hand-harvested flowers and laboratory testing for purity and active ingredients.